• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

byGursharan SohiandYuchen Dai
July 7, 2022
in Chronic Disease, Infectious Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. High dose dexamethasone was nonsuperior in regards to 60-day survival outcomes as compared with regular dose dexamethasone in COVID-19 patients with acute hypoxemic respiratory failure.

2. Continued positive airway pressure and high flow nasal oxygen did not reduce the need for mechanical ventilation in non-ventilated patients compared to standard oxygen therapy.

Level of Evidence Rating: 1 (Excellent)

Study Rundown: COVID-19 has accounted for millions of deaths worldwide. The virus can cause severe lung disease and acute hypoxemic respiratory failure (AHRF), the optimal management of which is not yet known. Previous studies have demonstrated that a 10-day course of dexamethasone at a low dose of 6 mg per day reduced 28-day mortality in patients with COVID-19. The present study sought to evaluate whether high dose dexamethasone was superior to the standard of care in improving mortality outcomes amongst COVID patients. Additionally, this trial aimed to describe the optimal oxygenation strategy in non-ventilated patients in an intensive care setting.

A randomized controlled trial of 550 patients with COVID-19 was conducted. In total, 277 received standard/low dose dexamethasone and 273 received high dose dexamethasone. 333 patients were not ventilated and were additionally randomized for oxygen therapy. From the low dose dexamethasone group, 56 received standard therapy, 57 continued positive airway pressure (CPAP), and 56 high flow nasal oxygen (HFNO2). In the high dose group, 53 received standard therapy, 52 CPAP, and 59 HFNO2. Overall, 144 patients died within 60 days of randomization including 74 patients in the low dose and 70 patients in the high dose groups. This finding was considered nonsignificant. There was also no significant difference in the requirement for ventilation in non-ventilated patients who had standard oxygen therapy compared to CPAP or HFNO2.

The present study found that high dose dexamethasone is nonsuperior to low dose dexamethasone in the management of COVID-19 patients with AHRF. As well, the authors concluded that HFNO2 and CPAP do not reduce the need for ventilation in non-ventilated patients compared to standard oxygen therapy alone. These findings are important as clinicians continue to make gains in understanding and treating COVID-19. The findings reported in this study are strengthened by the randomized controlled design of the trial as well as the large sample size. A primary limitation of this work is the low adherence to the designated treatment arm as well as the small number of patients per group for the oxygen therapy component of this trial. The findings described here may help to guide management and provoke further research into therapeutic options for COVID-19 patients.

Click here to read this study in JAMA Internal Medicine

RELATED REPORTS

High-flow nasal cannula oxygen compared with standard oxygen therapy not associated with significant reduction in mortality in patients with respiratory failure due to COVID-19 – The SOHO-COVID Randomized Clinical Trial

Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer

Third dose of BNT162b2 COVID-19 vaccine effective at decreasing risk of hospitalization [Classics Series]

Relevant reading: The use of high-flow nasal oxygen in the ICU as a first line therapy for acute hypoxemic respiratory failure secondary to coronavirus disease 2019

In Depth: [randomized controlled trial]: This study was a multi-center randomized controlled trial conducted in France. Eligible patients were adults admitted to the intensive care unit with COVID-19 who met criteria for AHRF (PaO2<70mmHg, SpO2<90% on room air, respiratory rate > 30 breaths per minute, labored breathing, respiratory distress, need for >6L of oxygen). All patients were randomized to either high or low dose dexamethasone, and patients who were not already requiring mechanical ventilation were additionally randomized to receive regular oxygen therapy, HFNO2 or CPAP. The primary outcome was time to death from all causes up to 60 days from trial initiation.

The rate of death within 60 days was 26.8% within the high dose group and 25.9% within the low dose group; the hazard ratio was 0.96 (95% confidence interval 0.69 to 1.33). There was no significant difference in low dose and high dose dexamethasone between patients who were (0.88, 0.58-1.29) versus were not mechanically ventilated (1.08, 0.64-1.83). In non-ventilated patients, the rate of requiring a ventilator at 28 days was 41.4% (32.0-50.4%) in patients treated with standard oxygen, 43% (33.3-52.2%) in patients treated with CPAP and 43.8% (34.5-52.6%) in those treated with HFNO2. The hazard ratio for requiring ventilation in standard oxygen therapy versus CPAP patients was 1.08 (0.71-.63) and was 1.04 (0.69-1.55) versus HFNO2.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #COVID mortalitydexamethasonehypoxemiarespiratory failure
Previous Post

Plasma p-tau217 is an accurate plasma biomarker of pathologic cerebral changes in patients with Down Syndrome

Next Post

Comparisons of invasive versus conservative management in chronic kidney disease in the ISCHEMIA-CKD trials

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

High-flow nasal cannula oxygen compared with standard oxygen therapy not associated with significant reduction in mortality in patients with respiratory failure due to COVID-19 – The SOHO-COVID Randomized Clinical Trial

October 2, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer

September 12, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

Third dose of BNT162b2 COVID-19 vaccine effective at decreasing risk of hospitalization [Classics Series]

July 18, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

The RECOVERY trial: Dexamethasone decreased mortality in hospitalized COVID-19 patients [Classics Series]

July 16, 2022
Next Post
Being overweight and obese associated with increased incidence of chronic kidney disease

Comparisons of invasive versus conservative management in chronic kidney disease in the ISCHEMIA-CKD trials

Smoking during pregnancy associated with aerobic fitness of children

Community-based and health-care based smoking cessation intervention models have similar efficacy

COVID-19 epidemiologic characteristics in Wuhan, China [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options